Taysha Q1 net loss $42.4M; FDA aligns on TSHA-102 BLA submission pathway

Taysha Gene Therapies, Inc.

2026-Q1 EPS reported -$0.12

Net loss $42.4M ($0.12/sh) vs $21.5M ($0.08/sh) Q1 2025; R&D expense doubled to $33.8M on PPQ and clinical costs.
Cash $276.6M; company expects runway into 2028.
FDA reaffirmed alignment on TSHA-102 BLA pathway including pivotal trial design, endpoints, and potential 6-month interim submission.
Dosing in REVEAL pivotal and ASPIRE trials on track for Q2 2026 completion; no treatment-related SAEs or DLTs to date.
BLA-enabling PPQ campaign initiated April 2026; completion expected Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 6, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2026, and recent business highlights.

View on SEC.gov

Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-207633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.